NAB-paclitaxel as third-line therapy after failure of gemcitabine and 5-fluorouracil (5-FU) based combinations in advanced gall bladder cancer patients

被引：0
|
作者：
Goel, V. [1 ]
Talwar, V. [1 ]
Patnaik, N. [2 ]
Raina, S. [1 ]
Singh, S. [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Med Oncol, New Delhi, India
[2] UCMS & GTB Hosp, Pathol, Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
241P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PHASE II STUDY OF DOCETAXEL AND 5-FLUOROURACIL (5-FU) WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH ADVANCED ESOPHAGEAL CANCER
    Hihara, J.
    Hamai, Y.
    Emi, M.
    Aoki, Y.
    Miyata, Y.
    Okada, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 238 - 238
  • [32] Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC).
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Bernuzzi, P
    Bertè, R
    Bidin, L
    Palladino, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 330S - 330S
  • [33] Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first-line metastatic pancreatic cancer (MPC): Updated results.
    Picozzi, Vincent J.
    Lin, Bruce Shih-Li
    Mandelson, Margaret T.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [34] A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer
    Riess, H
    Helm, A
    Niedergethmann, M
    Schmitt-Wolf, I
    Moik, M
    Hammer, C
    Zippel, K
    Weigang-Köhler, K
    Stauch, M
    Oettle, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 310S - 310S
  • [35] Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer
    Tsavaris, N
    Kosmas, C
    Gennatas, K
    Vadiaka, M
    Skopelitis, E
    Xila, V
    Rokana, S
    Margaris, E
    Zografos, G
    Papastratis, G
    Kouraklis, G
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (04) : 406 - 411
  • [36] 5-DAY IV INFUSION WITH 5-FLUOROURACIL (5-FU-NSC-19893) FOR GASTROENTERIC CARCINOMA AFTER FAILURE ON WEEKLY 5-FU THERAPY
    HUM, GJ
    BATEMAN, JR
    CANCER CHEMOTHERAPY REPORTS PART 1, 1975, 59 (06): : 1177 - 1179
  • [37] The effects of chronomodulated therapy with 5-fluorouracil (5-Fu) and folinic acid (Fa) on the toxicity and quality of life in patients with advanced gastric cancer
    Yalcin, B
    Akbulut, H
    Buyukcelik, A
    Sencan, O
    Demirkazik, A
    Onur, H
    Senler, FC
    Dincol, D
    Icli, F
    BIOLOGICAL RHYTHM RESEARCH, 2004, 35 (4-5) : 259 - 268
  • [38] Third-Line Chemotherapy with irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients
    Pasquini, Giulia
    Vasile, Enrico
    Caparello, Chiara
    Vivaldi, Caterina
    Musettini, Gianna
    Lencioni, Monica
    Petrini, Lacopo
    Fornaro, Lorenzo
    Falcone, Alfredo
    ONCOLOGY, 2016, 91 (06) : 311 - 316
  • [39] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [40] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
12345